Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2026-01-02 @ 4:35 AM
Study NCT ID:
NCT04564456
Status:
COMPLETED
Last Update Posted:
2021-01-20
First Post:
2020-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
Sponsor:
Respirent Pharmaceuticals Co Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09-22
Start Date Type:
ACTUAL
Primary Completion Date:
2020-10-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-12-31
Completion Date Type:
ACTUAL
First Submit Date:
2020-09-22
First Submit QC Date:
None
Study First Post Date:
2020-09-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-18
Last Update Post Date:
2021-01-20
Last Update Post Date Type:
ACTUAL